Agent and Method for Reducing Inflammatory Markers
OwnerMichael Chezinventor
Life of this patent
Estimating the term…
Abstract
A method for treating an autism spectrum condition includes administering an effective dose of a TNF-α inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum, as compared to normal conditions; and lowering at least one of the elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum. A TNF-α inhibiting agent includes at least one of Lenalinomide; Thalidomide; L-Carnosine; Infliximab; Etanercept; a stem cell preparation; derivatives thereof, isomers thereof, or pharmaceutically acceptable salts thereof.
Claims23
A method for treating an autism spectrum disorder or pervasive development disorder, comprising:
- administering an effective dose of a TNF-α inhibiting agent to a person having an autism spectrum disorder or pervasive development disorder and an elevated ratio of TNF-α in the cerebrospinal fluid to TNF-α in serum;
- and
- lowering the elevated ratio of TNF-α in the cerebrospinal fluid to TNF-α in the serum,
- wherein the TNF-α inhibiting agent is selected from the group consisting of thalidomide;
- l-carnosine;
- infliximab;
- etanercept;
- and derivatives, isomers, or pharmaceutically acceptable salts of the TNF-α inhibiting agent.
An agent comprising a TNF-α inhibiting agent that inhibits at least one of the elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum,
- wherein the TNF-α inhibiting agent is selected from the group consisting of lenalinomide;
- thalidomide;
- l-carnosine;
- infliximab;
- etanercept;
- and derivatives, isomers, or pharmaceutically acceptable salts of the TNF-α inhibiting agent.
A method for treating an autism spectrum disorder or pervasive development disorder, comprising:
- administering an effective dose of a TNF-α inhibiting agent to a patient having an autism spectrum disorder or pervasive development disorder and having an elevated ratio of TNF-α in the cerebrospinal fluid to TNF-α in serum;
- lowering the elevated ratio of TNF-α in the cerebrospinal fluid to TNF-α in the serum;
- and
- lowering a serum level of a cytokine,
- wherein the TNF-α inhibiting agent is selected from the group consisting of thalidomide;
- l-carnosine;
- infliximab;
- etanercept;
- a stem cell preparation;
- and derivatives, isomers, or pharmaceutically acceptable salts of the TNF-α inhibiting agent.
A method according to claim 21, wherein said stem cell preparation comprises at least one of pleuripotent, neuronally-derived, or mesenchymal stem cells.
Dependencies are inferred from the claim text.